Comparative Pharmacology
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus TAZICEF.
PANIXINE DISPERDOSE vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic